目的 探讨阿卡波糖联合诺和锐30治疗2型糖尿病血糖控制欠佳者的临床疗效。方法 南京大学医院收治的52例血糖控制欠佳的2型糖尿病患者随机分为治疗组（27例）和对照组（25例）。对照组给予诺和锐30注射液，2次/d，早晚餐前皮下注射。治疗组于三餐前口服阿卡波糖片，50 mg/次，3次/d，诺和锐30注射液的用法同对照组。治疗12周后，比较两组患者治疗前后空腹血糖（FBG）、餐后2 h血糖（2 h PG）、糖化血红蛋白（HbA1c）、体质量指数（BMI）、血脂变化情况及胰岛素用量。结果 治疗后，两组患者FBG、HbA1c均较治疗前明显降低，治疗前后差异有统计学意义（P<0.05）。治疗后，治疗组患者HbA1c水平明显低于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组全天七点血糖水平均较治疗前明显降低，同组治疗前后差异有统计学意义（P<0.05）；同时，治疗组三餐后2 h PG均显著低于对照组，两组比较差异有统计学意义（P<0.05）。治疗组血糖达标时间明显短于对照组，两组比较差异有统计学意义（P<0.05）。结论 阿卡波糖联合诺和锐30治疗血糖控制欠佳的2型糖尿病患者具有较好的临床疗效，可有效控制餐后血糖水平，具有良好的临床应用价值。

Objective To investigate the clinical effect of acarbose combined with Novomix 30 in the treatment of type 2 diabetes of patients who had a suboptimal response to therapy. Methods Fifty-two cases of type 2 diabetes in Hospital of Nanjing University, who had a suboptimal response to therapy, were randomly divided into treatment group (27 cases) and control group (25 cases). Patients in the control group were sc administered with Novomix 30 Injection before breakfast and dinner, twice daily; Patients in the treatment group were po administered with Acarbose Tablets, 50 mg/time, three times daily, while the usage of Novomix 30 Injection were the same as the control group. After 12 weeks of the continuous therapy, fasting blood glucose (FBG), 2 h post meal blood glucose (2 h PG), glycosylated hemoglobin A1c (HbA1c), body mass index (BMI), blood lipid, and the dosage of insulin in the two groups were compared. Results After the treatment, FBG and HbA1c of the two groups were significantly lower than those before the treatment, and the differences were statistically significant in the same group before and after the treatment (P < 0.05). After the treatment, the level of HbA1c in the treatment group was lower than that in the control group, with the significant difference between the two groups (P < 0.05). After the treatment, the blood sugar level of seven observation point throughout the day in the two groups were significantly decreased, and the differences were statistically significant in the same group before and after the treatment (P < 0.05). At the same time, 2 h PG after three meals of the treatment group was lower than that in the control group, with the significant difference between the two groups (P < 0.05). Blood sugar up to the standard time of the treatment group was obviously shorter than that in the control group, with the significant difference between the two groups (P < 0.05). Conclusion Acarbose combined Novomix 30 has a good clinical efficacy in the treatment of type 2 diabetes of patients who have a suboptimal response to therapy, and can effectively control the postprandial blood glucose, which has good clinical application value.